Peripheral neuropathy docetaxel

Docetaxel Myelosuppression, severe fluid retention Alopecia, fatigue, stomatitis, nausea, vomiting, diarrhea, peripheral neuropathy, nail disorder, skin reactions, hypersensitivity reactions... 

Docetaxel asthenia, peripheral neuropathy, alopecia, cardiovascular Fatigue, nausea, vomiting, skin toxicity, neuropathy, anemia, Mild (on administration days... 

Docetaxel, 75 mg/m2 every 3 weeks, combined with prednisone, 5 mg twice daily, has been shown to prolong survival in hormone-refractory metastatic prostate cancer. The most common adverse events were nausea, alopecia, and myelosuppression. Docetaxel can also cause fluid retention and peripheral neuropathy. 

The plant alkaloids (vincristine, vinblastine, vindesine and vinorelbine) and taxoids (paclitaxel, docetaxel) inhibit microtubule assembly and cause cell cycle arrest in mitosis. They particularly cause bone marrow depression, peripheral neuropathy (vincristine) and alopecia. Etoposide blocks the cell cycle before mitosis. 

Docetaxel Nausea and vomiting hypersensitivity reactions Bone marrow depression fluid retention peripheral neuropathy alopecia arthralgias myalgias cardiac coxiciiy mild Gl disturbances mucositis... 

Metabolism/elimination Hepatic metabolism Adverse reactions Alopeda, nausea/vomiting/diarrhea, myelosuppression (dose-limiting, granulocytopenia, and thrombocytopenia), hepatic toxidty, peripheral neuropathy, hypersensitivity reactions, myalgias/arthralgias, rare cardiovascular events, fluid retention/pulmonary edema (docetaxel). 

Mir O, Alexandre J, Tran A et al (2009) Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 20 736-740... 

On May 19, 2004, docetaxel was approved for the treatment of metastatic prostate cancer. The approval was based on the TAX327 study, a randomized, multicenter global clinical trial enrolling over 1000 men with metastatic, hormone-refractory prostate cancer. The study compared docetaxel 75 mg/m every 3 weeks and prednisone 5 mg twice a day with docetaxel 35 mg/m weekly five out of six weeks and prednisone 5 mg twice a day and mitoxantrone 75 ng/m every 3 weeks and prednisone 5 mg twice a day. Docetaxel, in combination with prednisone, given every 3 weeks showed a survival advantage of approximately 2.5 months over the control group in the trial p =. 009). The most common adverse events reported were nausea, alopecia, and bone marrow suppression. In addition, fluid retention and peripheral neuropathy, known effects of docetaxel, were... 

Adverse effects of paclitaxel and docetaxel are similar, being hypersensitivity reactions, bone marrow suppression, peripheral neuropathy, hair loss and cardiac arrhythmias. 

Toxicity Paclitaxel causes neutropenia, thrombocytopenia, a high incidence of peripheral neuropathy, and possible hypersensitivity reactions during infusion. Docetaxel causes neurotoxicity and bone marrow depression. 

Nervous system About 30% of patients treated with docetaxel develop symptoms of peripheral neuropathy [112 ]. Generally, the symptoms settle within months. Peripheral neuropathy is less frequent with docetaxel than with paclitaxel grade 3/4 sensory neuropathy occurs in about 5% of patients treated with docetaxel 100 mg/m [126 ]. Proximal and distal muscle weakness has also been reported (about 5% in a review of 186 patients in phase I and phase II studies) [127 ]. The pathogenesis, incidence, susceptibility factors, diagnosis, characteristics, and management of taxane-induced peripheral neuropathy have been critically reviewed [128 ]. 

New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996 46(1) 108-11. 

---